Syngen Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,067	2,136	2,014	1,837	1,931	1,471
Revenue Growth (YoY)	1.74%	6.10%	9.60%	-4.84%	31.22%	12.19%
Cost of Revenue	1,380	1,413	1,290	1,193	1,242	942.93
Gross Profit	687.05	723.59	723.94	643.92	688.15	528.34
Selling, General & Admin	328.5	339.07	354.38	302.88	262.63	197.02
Research & Development	62.15	60.56	59.34	46.76	45.32	49.52
Operating Expenses	390.97	396.61	420.64	341.06	325.78	246.86
Operating Income	296.08	326.98	303.3	302.86	362.38	281.48
Interest Expense	-5.05	-5.65	-9.28	-8.86	-5.07	-3.21
Interest & Investment Income	2.37	2.38	2.05	1.43	0.61	0.32
Earnings From Equity Investments	4.43	8.09	-5.32	36.08	26.64	14.81
Currency Exchange Gain (Loss)	-0.32	-0.32	5.32	-1.93	10.29	-4.31
Other Non Operating Income (Expenses)	3.78	3.62	4.18	4.49	1.58	7.87
EBT Excluding Unusual Items	301.28	335.09	300.25	334.07	396.42	296.95
Gain (Loss) on Sale of Investments	0.3	0.3	-0.49	0.02	0.21	0.98
Gain (Loss) on Sale of Assets	-0.15	-0.15	-0.15	-0.28	-0.21	-0.63
Asset Writedown	-0.4	-0.4	-	-	-	-1.81
Pretax Income	301.03	334.84	299.61	333.8	396.42	295.49
Income Tax Expense	57.2	63.25	59.4	58.98	75.18	57.72
Net Income	243.83	271.59	240.21	274.83	321.24	237.77
Net Income to Common	243.83	271.59	240.21	274.83	321.24	237.77
Net Income Growth	0.92%	13.07%	-12.60%	-14.45%	35.10%	10.31%
Shares Outstanding (Basic)	28	27	27	27	27	27
Shares Outstanding (Diluted)	28	27	27	27	27	27
Shares Change (YoY)	2.61%	0.02%	-	-0.01%	-0.00%	-0.01%
EPS (Basic)	8.77	10.02	8.86	10.14	11.85	8.77
EPS (Diluted)	8.76	10.01	8.85	10.13	11.84	8.76
EPS Growth	-1.57%	13.11%	-12.64%	-14.44%	35.16%	10.33%
Free Cash Flow	324.34	255.92	287.83	323.23	-306.79	274.83
Free Cash Flow Per Share	11.65	9.43	10.61	11.91	-11.31	10.13
Dividend Per Share	5.000	5.000	5.000	5.000	5.000	4.000
Dividend Growth	-	-	-	-	25.00%	14.29%
Gross Margin	33.23%	33.87%	35.95%	35.05%	35.64%	35.91%
Operating Margin	14.32%	15.30%	15.06%	16.48%	18.77%	19.13%
Profit Margin	11.79%	12.71%	11.93%	14.96%	16.64%	16.16%
Free Cash Flow Margin	15.69%	11.98%	14.29%	17.59%	-15.89%	18.68%
EBITDA	398.79	431.71	402.1	386.21	432.93	347.82
EBITDA Margin	19.29%	20.21%	19.97%	21.02%	22.43%	23.64%
D&A For EBITDA	102.71	104.73	98.8	83.35	70.56	66.34
EBIT	296.08	326.98	303.3	302.86	362.38	281.48
EBIT Margin	14.32%	15.30%	15.06%	16.48%	18.77%	19.13%
Effective Tax Rate	19.00%	18.89%	19.83%	17.67%	18.96%	19.53%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.